New cell death process linked to Alzheimer's disease

Researchers have identified a previously unknown mechanism called karyoptosis that appears to drive the death of brain cells in Alzheimer's disease and frontotemporal dementia. The discovery, based on analysis of human brain tissue, points to a potential new target for treatments aimed at slowing neuron loss.

Scientists at King's College London, working with the UK Dementia Research Institute, examined 3,000 brain cells from 28 individuals with either frontotemporal dementia or advanced Alzheimer's. They detected signs of karyoptosis in 35 percent of cells from the frontal cortex of Alzheimer's patients, compared with 15 percent in healthy older adults.

Karyoptosis begins when toxic proteins accumulate inside neurons. This buildup destabilizes the nuclear membrane, causing the cell's nucleus to shrink and eventually break apart. Laboratory tests on rat neurons showed that blocking the interaction between p38 MAP kinase and LaminB1 reduced markers of this process.

"This study is the culmination of a 10-year journey at King's," said Dr. Manolis Fanto, Reader in Functional Genomics at the Institute of Psychiatry, Psychology and Neuroscience. Dr. Rebecca Casterton, first author and Senior Researcher at the UK Dementia Research Institute, added that the work lays out a road map for how karyoptosis operates.

The findings were published in Nature Communications. Alzheimer's Research UK and the Biotechnology and Biological Sciences Research Council provided primary funding.

Verwandte Artikel

Illustration of mutated blood cells entering the brain through the blood-brain barrier, linked to Alzheimer's pathology.
Bild generiert von KI

Study finds blood-cancer-linked mutations in brain immune cells tied to Alzheimer’s pathology

Von KI berichtet Bild generiert von KI Fakten geprüft

Researchers at Boston Children’s Hospital report that mutations commonly associated with clonal blood-cell expansion and some blood cancers were enriched in microglia-like immune cells in Alzheimer’s brains and were also detectable in matched blood samples. The Cell study proposes that age- or injury-related weakening of the blood-brain barrier could allow mutated blood immune cells to enter the brain, potentially amplifying inflammation and contributing to neurodegeneration.

Researchers at the University of California, Riverside have proposed that amyloid beta disrupts tau protein function inside neurons, potentially triggering Alzheimer's disease. The findings challenge the focus on external plaques as the primary cause.

Von KI berichtet

A team of researchers led by Professor Yan-Jiang Wang has published a review arguing that Alzheimer's disease requires integrated treatments targeting multiple factors, not single causes. New drugs like lecanemab and donanemab offer modest benefits by slowing decline, but fall short of reversal. The paper, in Science China Life Sciences, emphasizes genetics, aging, and systemic health alongside amyloid-beta and tau proteins.

Diese Website verwendet Cookies

Wir verwenden Cookies für Analysen, um unsere Website zu verbessern. Lesen Sie unsere Datenschutzrichtlinie für weitere Informationen.
Ablehnen